We thank Kang et al. [1] for their trial ML17032 published in the recent issue of Annals of Oncology. This confirmed the noninferiority of capecitabine to infusional 5-fluorouracil as part of palliative combination chemotherapy for advanced gastric cancer. In the accompanying editorial, Wong and Cunningham [2] make the important point that current evidence indicates doublet chemotherapy regimens are inferior to triplet regimens in this setting.
This issue is not unique to upper gastrointestinal cancer and the ageing population in the Western world can be expected to lead to a marked increase in the number of elderly patients seeking treatment over the coming decades.
One might argue that the focus of evidence on the younger minority accurately reflects sensible use of chemotherapy by limiting it to those in whom the risk-benefit trade-off is likely to be favourable. However, evidence indicates that age is not a negative predictive factor for response or a negative prognostic factor for survival outcomes in gastric or oesophageal cancer [5] . It may be that the toxicity of triplet or even doublet regimens may indeed outweigh any anticancer benefit in the elderly. Only by assessing single-agent, doublet and triplet therapy at appropriate doses in the elderly population, we will secure a comprehensive evidence base and determine a standard treatment in this important group of patients. 
